{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:56:04Z","timestamp":1769147764971,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2009,5,4]],"date-time":"2009-05-04T00:00:00Z","timestamp":1241395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1136\/ard.2008.105064","type":"journal-article","created":{"date-parts":[[2009,5,6]],"date-time":"2009-05-06T02:12:30Z","timestamp":1241575950000},"page":"387-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?"],"prefix":"10.1016","volume":"69","author":[{"given":"A","family":"Finckh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Brulhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U A","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Courvoisier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Kyburz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Dudler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Gabay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2008.105064_bib1","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.105064_bib2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.105064_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib4","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.2008.105064_bib5","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1002\/art.11358","article-title":"Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.","volume":"48","author":"Redlich","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib6","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/ard.2005.045062","article-title":"Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.","volume":"65","author":"Finckh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.105064_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2165\/00003495-200868050-00003","article-title":"Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.","volume":"68","author":"Lutt","year":"2008","journal-title":"Drugs"},{"key":"10.1136\/ard.2008.105064_bib8","first-page":"1021","article-title":"Is there a rationale for switching from one anti-tumor necrosis factor agent to another?","volume":"31","author":"Haraoui","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2008.105064_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.105064_bib10","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","article-title":"Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice.","volume":"46","author":"Bombardieri","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.105064_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1136\/ard.2008.105064_bib12","first-page":"S183","article-title":"Failure of adalimumab in patients with rheumatoid arthritis [abstract].","volume":"56","author":"Gullick","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib13","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo controlled trial.","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2008.105064_bib14","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.105064_bib16","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","article-title":"B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.","volume":"56","author":"Finckh","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"suppl","key":"10.1136\/ard.2008.105064_bib17","first-page":"ii28","article-title":"Rituximab may be more effective than switching to an alternative TNF inhibitor in rheumatoid arthritis patients who have failed other TNF inhibitors [abstract].","volume":"47","author":"Venkatachalam","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.105064_bib18","first-page":"S304","article-title":"Comparison of the effectiveness of rituximab and a third TNF blocking agent after failure of two TNF blocking agents in daily clinical practice [abstract].","volume":"58","author":"Blom","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib19","first-page":"S899","article-title":"The efficacy of rituximab in patients with rheumatoid arthritis (RA) who previously failed one or two anti-TNFs as compared to the efficacy of switching between anti-TNFs: a registry study [abstract].","volume":"58","author":"van Vollenhoven","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/rheumatology\/39.5.542","article-title":"Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in rheumatoid arthritis.","volume":"39","author":"Uitz","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.105064_bib21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/art.21491","article-title":"The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.","volume":"54","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib23","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D'Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1136\/ard.2008.105064_bib24","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib25","unstructured":"Smolen J, Kay J, Doyle M, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized double-blind, placebo-controlled trial [abstract]. Ann Rheum Dis 2008;67(suppl II):50\u20131."},{"key":"10.1136\/ard.2008.105064_bib26","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2008.105064_bib27","unstructured":"Yazici Y, Erkan D,. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 2004;63:607\u20138; author reply 608."},{"key":"10.1136\/ard.2008.105064_bib28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","article-title":"Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.","volume":"47","author":"Karlsson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2008.105064_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/art.20115","article-title":"Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.","volume":"50","author":"Buch","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib30","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","article-title":"Therapeutic strategies for rheumatoid arthritis.","volume":"350","author":"O'Dell","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2008.105064_bib31","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/art.11156","article-title":"Understanding the window of opportunity concept in early rheumatoid arthritis.","volume":"48","author":"Boers","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2008.105064_bib32","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/rheumatology\/kel054","article-title":"Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.","volume":"45","author":"Solau-Gervais","year":"2006","journal-title":"Rheumatology (Oxford)"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724196264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2008.105064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:43:12Z","timestamp":1739522592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724196264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S0003496724196264"],"URL":"https:\/\/doi.org\/10.1136\/ard.2008.105064","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2008.105064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 \u00a9 Finckh et al 2010. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}